Updated:
State Science & Technology Investment
State Science & Technology Investment channels Chinese state capital into hard-tech startups, bridging policy and venture in Shanghai.
State Science & Technology Investment
State Science & Technology Investment represents a distinct model of Chinese government-guided venture capital, structured to convert national R&D priorities into investable companies. The entity channels capital from state-level science and technology programs into early- and growth-stage enterprises, typically in sectors identified as critical under China's five-year economic plans. Its portfolio concentrates on enterprises emerging from university labs, military-civilian fusion projects, and state-backed incubators. The firm's deployment spans semiconductors, quantum computing, renewable energy, advanced materials, and precision medicine. It participates across the venture lifecycle, from seed-stage technology spinoffs to expansion rounds for companies scaling domestically. Confirmed sector exposures include integrated circuit design, novel battery chemistries, and autonomous systems. The geographic footprint is heavily weighted toward the Yangtze River Delta, with additional exposure to the Greater Bay Area and select projects in Northeast China's legacy industrial bases. The team operates without publicly disclosed headcount, drawing investment professionals from China's science bureaucracy and state-owned enterprise ecosystem. The firm does not maintain visible co-investor structures with foreign limited partners. Adjacent vehicles and philanthropic entities are similarly opaque. March 2024: The firm participated in a $200 million Series C for a Chinese AI chip developer, underscoring sustained state appetite for semiconductor independence amid tightening export controls. Its structural differentiator is the embedded mandate: unlike return-maximizing venture firms, State Science & Technology Investment measures success in patents filed, import-substitution milestones, and alignment with ministerial technology roadmaps. This creates a portfolio that functions as an extension of industrial policy rather than a purely financial enterprise.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Sector focus
Frequently asked questions
Who ultimately controls investment decisions at State Science & Technology Investment?
The firm operates under the direction of China's state scientific apparatus, likely with ultimate oversight from the Ministry of Science and Technology or a related provincial-level commission. Specific named principals are not publicly disclosed, consistent with many state-directed investment platforms. Portfolio construction reflects ministerial research priorities rather than the mandate of a single identifiable CIO or managing partner.
Does the firm invest alongside foreign VCs or accept foreign LP capital?
Given its state-directed mandate, particularly in dual-use and semiconductor technologies, the firm generally does not co-invest with foreign limited partners. Its capital stack is believed to derive from domestic sources including state scientific funds, provincial government guidance funds, and state-owned enterprises, per public record.
What investment stages does State Science & Technology Investment typically target?
The firm engages across the early-stage and growth-stage spectrum, from seed rounds for university and lab spinoffs to larger expansion rounds for companies entering commercial scale. This continuity allows it to shepherd technologies from prototype through industrial deployment. Later-stage involvement often accelerates a portfolio company's path into China's domestic supply chains.
Which sectors does the firm explicitly focus on?
The portfolio concentrates on sectors designated as strategic in China's national plans: semiconductors, artificial intelligence, clean energy, advanced manufacturing, biotechnology, and new materials. These alignments are observable in the firm's known deal activity, including investments in chip design and battery technology companies.
How is this firm different from a commercial Chinese VC like Qiming or Sequoia China?
While commercial VCs optimize for financial returns and IPO exits, State Science & Technology Investment prioritizes technology sovereignty and industrial policy outcomes. Its performance metrics are tied to patent generation, import substitution, and ecosystem maturity rather than IRR or DPI. It also operates with a patient-capital timeline untethered from fund cycle pressures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: